Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.47 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.47 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.47 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672467 | 0.89 | TRPV1 (0.49) | TRPV1 | |
| SCHEMBL657904 | 0.78 | TRPV1 (0.46) | TRPV1MAPK14MAPK9DDR2MAPK13 | |
| SCHEMBL25510561 | 0.78 | TRPV1 (0.47) | TRPV1MAPK14MAPK9DDR2MAPK13 | |
| SCHEMBL2787544 | 0.74 | GRN (0.76) | TRPV1MAPK14MAPK9DDR2MAPK13 | |
| SCHEMBL2688130 | 0.74 | TRPV1 (0.72) | TRPV1 | |
| SCHEMBL2688133 | 0.71 | MAPK14 (0.51) | TRPV1MAPK14MAPK9DDR2MAPK13 | |
| SCHEMBL1015668 | 0.70 | MAPK14 (0.61) | MAPK14MAPK9DDR2MAPK13MAPK12 | |
| SCHEMBL29396851 | 0.70 | MAPK14 (0.50) | TRPV1MAPK14MAPK9DDR2MAPK13 | |
| SCHEMBL1012342 | 0.70 | MAPK14 (0.50) | TRPV1MAPK14MAPK9DDR2MAPK13 | |
| SCHEMBL12705326 | 0.69 | GRN (0.62) | MAPK14MAPK13MAPK12MAPK11GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334315-B2 | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2012-12-18 | — | — | US | disclosed |
| EP-2427436-A1 | SUBSTITUTED AROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-03-14 | — | — | EP | disclosed |
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003795-A1 | Substituted Aromatic Carboxamide and Urea Derivatives as Vanilloid Receptor Ligands | TRPV1, UTS2R, CNR2 | TRPV1 1/4885MAPK14 2563/4885MAPK9 2667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.